Search

Displaying results 3281 - 3290 of 4262 in total
  1. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifi...

  2. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It is being developed by Alizyme of the UK.

  3. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

  4. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  5. Drug

    Bizalimogene ralaplasmid

    go.drugbank.com/drugs/DB16113
    Investigational

    Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related

  6. Drug

    Eflepedocokin alfa

    go.drugbank.com/drugs/DB16366
    Investigational

    [A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]

  7. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

  8. Drug

    Efavaleukin alfa

    go.drugbank.com/drugs/DB16149
    Investigational

    Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

  9. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis

  10. Drug

    AVR-RD-01

    go.drugbank.com/drugs/DB17651
    Investigational

    AVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.